Osteoprotegerina protege os músculos de camundongos com distrofia muscular
Canada – pacientes com distrfoia muscular podem apresentar osteoporose e a causa não está totalemnte esclarecida. Nesta pesquisa os autores identificaram uma proteína, a osteoprotegerina, sendo produzida pelo músculo. Ela é responsável pela diferenciação de osteoclastos e remodelamento ósseo. A administração de osteoprotegerina de origem muscular promoveu aumento de força e redução das alterações patológicas dos músculos de camundongos com distrofia muscular.
O resumo em inglês pode ser lido abaixo:
(American Journal of Pathology, 2015) Osteoprotegerin Protects against Muscular Dystrophy
Sébastien S. Dufresne, Nicolas A. Dumont, Patrice Bouchard, Éliane Lavergne, Josef M. Penninger, Jérôme Frenette – Canada
Receptor-activator of NF-κB, its ligand RANKL, and the soluble decoy receptor osteoprotegerin are the key regulators of osteoclast differentiation and bone remodeling. Although there is a strong association between osteoporosis and skeletal muscle atrophy/dysfunction, the functional relevance of a particular biological pathway that synchronously regulates bone and skeletal muscle physiopathology still is elusive. Here, we show that muscle cells can produce and secrete osteoprotegerin and pharmacologic treatment of dystrophic mdx mice with recombinant osteoprotegerin muscles. (Fc mitigates the loss of muscle force in a dose-dependent manner and preserves muscle integrity, particularly in fast-twitch extensor digitorum longus.) Our data identify osteoprotegerin as a novel protector of muscle integrity, and it potentially represents a new therapeutic avenue for both muscular diseases and osteoporosis.
